Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Coinbase Global, Inc. (COIN) vs BIO-TECHNE Corp (TECH) Price & Performance

Coinbase Global, Inc.Trade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Coinbase Global, Inc. vs BIO-TECHNE Corp — how do they compare? Coinbase Global, Inc. trades at $175.64 (market cap $47.08B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Coinbase Global, Inc. is far larger — about 4.1× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Coinbase Global, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coinbase Global, Inc. for 78 Days and BIO-TECHNE Corp for 63 Days on average.

COINTECH
Market Cap
$47.08B$11.37B
Volume
7,082,9283,153,511
Sector
FinancialsHealth
52-Week High
$387.00$72.61
52-Week Low
$141.09$43.31
Typical Hold Time
78 Days63 Days
Enterprise Value
$44.73B$11.40B
Dividend Yield
—0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Coinbase Global, Inc.

COIN trades at $178.45, down 3.92% with bearish technical signals. The stock shows mixed fundamentals with strong revenue growth to $7.18B in 2025 but negative net income margin of -15.72% and recent earnings misses. Analyst consensus remains positive with 55% buy ratings and $211.55 price target, while technical indicators show support at $177 and resistance at $180.

Outlook remains cautiously optimistic given analyst support and recent CFTC approval for derivatives expansion, but risks include volatile earnings performance, high valuation multiples, and regulatory uncertainty. The stock's current price near support levels presents potential entry point for long-term investors despite near-term headwinds.

BIO-TECHNE Corp

TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.

Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

COIN
76% Buy24% Sell
Avg holding period · 78 Days
TECH

No sentiment data available yet.

Top news

Latest headlines on both assets

About Coinbase Global, Inc.

Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.

Read more on COIN →

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH →